A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab
2012-0001
Phase 1 other active
Quick answer
A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab for unresectable advanced or metastatic solid cancer is a Phase 1 program (other) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- unresectable advanced or metastatic solid cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active